Cannabis and Inflammatory Bowel Disease Research: Clinical Evidence and Trials

Executive Summary

Cannabis-based therapies are emerging as a promising treatment avenue for inflammatory bowel disease (IBD), with New York's Office of Cannabis Management launching a landmark clinical study in May 2026 to evaluate medicinal cannabis efficacy for Crohn's disease and ulcerative colitis patients. This development represents a significant milestone in the convergence of cannabis medicine and gastroenterology, as approximately 3.1 million American adults currently live with IBD according to the Centers for Disease Control and Prevention. The New York study joins a growing body of international research examining how cannabinoids—particularly CBD and THC—interact with the endocannabinoid system to potentially reduce intestinal inflammation, manage pain, and improve quality of life for patients who often face limited treatment options. While preclinical evidence and patient surveys suggest therapeutic potential, rigorous clinical trials remain sparse, making state-sponsored research initiatives critical for establishing evidence-based treatment protocols. The intersection of cannabis policy reform and medical research is creating unprecedented opportunities to investigate botanical interventions for chronic inflammatory conditions that affect millions of patients and generate billions in annual healthcare costs.

Why This Matters

The convergence of cannabis research and IBD treatment addresses a critical unmet medical need affecting over 3 million Americans, with annual direct healthcare costs exceeding $14.6 billion. Inflammatory bowel disease encompasses two primary conditions: Crohn's disease and ulcerative colitis. Both involve chronic inflammation of the gastrointestinal tract, causing debilitating symptoms including severe abdominal pain, persistent diarrhea, rectal bleeding, weight loss, and fatigue. Conventional treatments include immunosuppressants, biologics, corticosteroids, and in severe cases, surgical bowel resection. However, many patients experience inadequate symptom control, intolerable side effects, or treatment failure over time. The patient population is substantial and growing. The CDC reports that IBD prevalence has increased significantly since 1999, with diagnosis rates climbing among younger adults and adolescents. Patients face lifelong disease management, frequent hospitalizations, reduced work productivity, and diminished quality of life. Many turn to cannabis products outside formal medical channels, with surveys indicating that 10-15% of IBD patients currently use cannabis for symptom management despite limited clinical evidence. For the cannabis industry, IBD represents a significant medical market opportunity. State medical marijuana programs increasingly list IBD as a qualifying condition, with New York, Pennsylvania, Ohio, Illinois, and Massachusetts among states explicitly including Crohn's disease or ulcerative colitis in their medical cannabis statutes. The potential patient population and chronic nature of IBD create sustained demand for effective cannabis-based therapies. Healthcare systems and insurers have financial stakes in identifying effective IBD treatments. Biologic medications like infliximab and adalimumab cost $30,000-$60,000 annually per patient. If cannabis-based interventions prove effective as adjunct or alternative therapies, they could reduce overall treatment costs and improve patient outcomes. Conversely, without rigorous clinical evidence, insurers remain reluctant to cover cannabis treatments, leaving patients to pay out-of-pocket costs ranging from $200-$600 monthly for medical cannabis products. Gastroenterologists and IBD specialists increasingly field patient questions about cannabis use. The lack of high-quality clinical data creates ethical dilemmas for physicians who must balance patient autonomy with evidence-based medicine principles. State-sponsored research initiatives provide pathways to generate the clinical evidence necessary for informed medical decision-making.

Background and History

The investigation of cannabis for inflammatory bowel disease spans three decades, evolving from anecdotal patient reports through preclinical research to the current era of formal clinical trials.

Early Anecdotal Evidence (1990s-2000s)

Patient advocacy communities first documented cannabis use for IBD symptom management in the 1990s, particularly within California's medical marijuana patient population following Proposition 215's passage in 1996. Crohn's disease and ulcerative colitis patients reported that cannabis smoking or ingestion reduced abdominal pain, decreased bowel movement frequency, and stimulated appetite during disease flares. These anecdotal accounts circulated through patient support groups and early internet forums but received minimal attention from the medical establishment. The first formal patient surveys emerged in the early 2000s. A 2004 survey of IBD patients in the United Kingdom found that approximately 12% had used cannabis for symptom relief, with most reporting subjective improvement in pain and diarrhea. Similar surveys in Canada and Israel documented comparable usage patterns, establishing that a significant minority of IBD patients were self-medicating with cannabis despite the absence of clinical evidence or physician guidance.

Endocannabinoid System Discovery (1990s-2000s)

Parallel scientific developments provided biological plausibility for cannabis effects on intestinal inflammation. Researchers identified cannabinoid receptors CB1 and CB2 throughout the gastrointestinal tract in the 1990s. CB1 receptors are abundant in the enteric nervous system, while CB2 receptors appear on immune cells within intestinal tissue. Studies demonstrated that the endocannabinoid system regulates intestinal motility, visceral pain perception, and immune responses—all relevant to IBD pathophysiology. In 2003, researchers at the University of Bologna published findings in the Journal of Clinical Investigation showing that endocannabinoid levels were elevated in colonic tissue from ulcerative colitis patients, suggesting the endocannabinoid system activates as a protective response to inflammation. This discovery positioned cannabinoid-based therapies as potentially working with natural physiological mechanisms rather than against them.

Preclinical Research Phase (2005-2015)

Animal models of colitis became the primary research tool for investigating cannabinoid effects on intestinal inflammation. Multiple studies using chemically-induced colitis in mice and rats demonstrated that both THC and CBD reduced inflammatory markers, decreased disease severity scores, and promoted intestinal healing. A landmark 2011 study published in PLOS ONE by researchers at the University of Bath showed that CBD reduced inflammation in mouse colitis models through mechanisms independent of CB1 and CB2 receptors, suggesting multiple therapeutic pathways. Research teams in Israel, Italy, and Canada led this preclinical work. Studies identified that cannabinoids modulated cytokine production, reduced neutrophil infiltration into intestinal tissue, and decreased intestinal permeability—the "leaky gut" phenomenon associated with IBD. However, translating these animal findings to human patients remained a significant challenge, as rodent colitis models imperfectly replicate the complex immunology of human IBD.

First Human Clinical Trials (2010-2018)

The first controlled clinical trial of cannabis for Crohn's disease was published in 2013 by researchers at Meir Medical Center in Israel. This small pilot study enrolled 21 patients with refractory Crohn's disease who smoked cannabis cigarettes containing 23% THC and 0.5% CBD twice daily for eight weeks. The results, published in Clinical Gastroenterology and Hepatology, showed significant improvement in disease activity scores and quality of life measures, though objective inflammatory markers like C-reactive protein did not significantly decrease. The study demonstrated feasibility and safety but was too small to establish definitive efficacy. A subsequent Israeli study published in 2018 in the European Journal of Gastroenterology & Hepatology examined CBD-rich cannabis oil (15% CBD, 4% THC) in 46 Crohn's disease patients. This randomized, placebo-controlled trial found that cannabis oil significantly improved quality of life and reduced symptom severity, but again failed to demonstrate significant changes in objective inflammatory biomarkers or endoscopic disease activity. These mixed results—subjective improvement without clear anti-inflammatory effects—became a recurring pattern in early cannabis-IBD research. Researchers at the University of Calgary published a systematic review in 2018 analyzing all available clinical evidence for cannabis in IBD. The review identified only three randomized controlled trials meeting quality criteria, concluding that while cannabis appeared to improve symptoms and quality of life, evidence for true disease modification remained insufficient. The authors called for larger, longer-duration trials with objective endpoints including endoscopic assessment and histological analysis.

Medical Cannabis Program Expansion (2015-2020)

As clinical research slowly progressed, state medical marijuana programs increasingly added IBD as a qualifying condition. New York included inflammatory bowel disease in its medical cannabis program at launch in 2016 under the Compassionate Care Act. Pennsylvania added Crohn's disease and ulcerative colitis as qualifying conditions in 2018. Ohio included IBD when its medical marijuana program became operational in 2019. By 2020, approximately 15 states explicitly listed Crohn's disease, ulcerative colitis, or inflammatory bowel disease among qualifying conditions for medical cannabis access. This policy expansion occurred despite limited clinical evidence, reflecting patient advocacy pressure and legislative recognition of unmet medical needs. Patient testimony before state legislatures emphasized the debilitating nature of IBD, the limitations of conventional treatments, and anecdotal benefits from cannabis use. Gastroenterology professional organizations generally maintained neutral positions, neither endorsing nor opposing medical cannabis access for IBD patients while emphasizing the need for more research.

COVID-19 Pandemic Impact (2020-2022)

The COVID-19 pandemic disrupted ongoing clinical trials and delayed new research initiatives. However, the pandemic also accelerated telehealth adoption in medical cannabis programs, improving access for IBD patients with mobility limitations or those living in rural areas. Researchers adapted protocols to include remote assessments and home-based data collection, methodologies that would influence subsequent trial designs. During this period, several observational studies were published analyzing real-world medical cannabis use among IBD patients. A 2021 study in the Journal of Clinical Medicine analyzed data from 127 Crohn's disease patients using medical cannabis in Canada, finding that 59% reported reduced opioid use and 47% discontinued at least one conventional IBD medication. While observational data cannot establish causation, these studies documented usage patterns and safety profiles in real-world settings.

Current Research Landscape (2023-2026)

The period from 2023 to 2026 has seen renewed momentum in cannabis-IBD research, driven by federal policy shifts and state-level research initiatives. The FDA's evolving stance on cannabis research, combined with DEA rescheduling discussions, has reduced some regulatory barriers to conducting clinical trials with cannabis products. New York's Office of Cannabis Management announced its clinical study initiative in May 2026, representing the first state regulator-sponsored trial specifically examining cannabis for IBD. The study design includes both Crohn's disease and ulcerative colitis patients, with plans to evaluate multiple cannabinoid formulations including THC-dominant, CBD-dominant, and balanced ratio products. The trial will incorporate objective endpoints including fecal calprotectin levels, endoscopic assessment, and histological analysis—addressing limitations of earlier studies that relied primarily on subjective symptom reporting. Concurrent research initiatives are underway at academic medical centers. The University of California San Diego launched a trial in 2024 examining CBD isolate versus full-spectrum cannabis extract for ulcerative colitis, with results expected in 2027. Researchers at the University of Colorado are conducting a dose-finding study for THC in Crohn's disease patients, examining whether higher doses provide greater anti-inflammatory effects. The Crohn's and Colitis Foundation awarded research grants totaling $2.3 million in 2025 for cannabis-related IBD studies, marking the first time the major patient advocacy organization directly funded cannabis research.

Key Players

New York Office of Cannabis Management

The New York Office of Cannabis Management (OCM), established under the Marijuana Regulation and Taxation Act in 2021, oversees both the state's medical cannabis program and adult-use market. The OCM's research division, created in 2024, has a legislative mandate to sponsor clinical studies examining medical cannabis efficacy for qualifying conditions. The IBD study represents the OCM's first major clinical trial initiative, with a reported budget of $4.8 million over three years. The agency partnered with academic medical centers including Columbia University Irving Medical Center and NYU Langone Health to conduct the multi-site trial.

Academic Research Institutions

Several universities have established specialized research programs examining cannabis for IBD. The University of Calgary's Cumming School of Medicine operates a dedicated cannabis research laboratory that has published multiple studies on cannabinoid effects in colitis models. Researchers there developed novel cannabinoid formulations designed to target intestinal tissue specifically, reducing systemic exposure and potential side effects. Tel Aviv University and the Hebrew University of Jerusalem in Israel have produced much of the foundational clinical research on cannabis for IBD. Israeli researchers benefit from a regulatory environment that has historically been more permissive for cannabis research, allowing earlier initiation of human trials. The Israeli Ministry of Health has licensed over 100 physicians to prescribe cannabis for IBD patients, creating a large patient population for observational research.

Pharmaceutical and Cannabis Companies

Several companies are developing cannabinoid-based therapies specifically formulated for IBD. GW Pharmaceuticals, now owned by Jazz Pharmaceuticals, conducted early-stage research on Epidiolex (pharmaceutical-grade CBD) for ulcerative colitis before discontinuing the program in 2019 due to disappointing Phase 2 results. The company found that CBD alone, at doses effective for epilepsy, did not significantly reduce intestinal inflammation in ulcerative colitis patients. Tilray Brands partnered with the University of California San Diego in 2023 to supply cannabis products for IBD clinical trials. The company provides standardized, pharmaceutical-grade cannabis extracts with consistent cannabinoid profiles, addressing a major challenge in cannabis research where product variability can confound results. Smaller cannabis companies including Cresco Labs and Curaleaf have developed product lines marketed toward IBD patients, typically featuring balanced THC:CBD ratios in tincture or capsule form. These products are available through state medical cannabis programs but lack FDA approval and are not marketed with specific disease claims due to federal regulations.

Patient Advocacy Organizations

The Crohn's and Colitis Foundation, the largest IBD patient advocacy organization in North America, has evolved its position on cannabis research over the past decade. While initially cautious, the foundation began funding cannabis-related research in 2025, signaling recognition of patient interest and emerging scientific evidence. The organization maintains that patients should not use cannabis outside legal medical programs and emphasizes the need for rigorous clinical trials. Patients for Medical Cannabis, a grassroots advocacy group, has lobbied state legislatures to include IBD as a qualifying condition in medical marijuana programs. The organization collects patient testimonials and conducts informal surveys documenting cannabis use patterns among IBD patients, data that has informed policy discussions in multiple states.

Medical Professional Organizations

The American Gastroenterological Association (AGA) published clinical guidance in 2020 addressing cannabis use among IBD patients. The guidance acknowledges that many patients use cannabis but notes insufficient evidence to recommend it as a treatment. The AGA recommends that gastroenterologists discuss cannabis use with patients, document usage in medical records, and counsel patients about potential risks including drug interactions and impaired cognition. The American College of Gastroenterology maintains a similar position, emphasizing that cannabis should not replace evidence-based IBD therapies but recognizing patient autonomy in treatment decisions. Both organizations have called for increased federal research funding to generate higher-quality clinical evidence.

Legal and Regulatory Framework

Cannabis research for medical conditions operates within a complex regulatory landscape involving federal drug scheduling, state medical marijuana laws, FDA oversight, and DEA licensing requirements. Cannabis remains a Schedule I controlled substance under the Controlled Substances Act, 21 U.S.C. § 812, which classifies it alongside heroin and LSD as having no accepted medical use and high abuse potential. This federal classification creates significant barriers to clinical research. Researchers must obtain a Schedule I license from the DEA, register their research protocol with the FDA, and source cannabis from federally approved suppliers—historically limited to a single facility at the University of Mississippi. The DEA expanded the number of licensed cannabis manufacturers for research purposes in 2021, approving additional cultivators to supply clinical trials. This expansion has gradually increased cannabis availability for research, though researchers report that obtaining specific cannabinoid profiles and product forms remains challenging compared to conventional pharmaceutical research. State medical marijuana laws operate independently of federal scheduling. Under principles of federalism, states can establish their own controlled substance policies, though they cannot override federal law. As of 2026, 38 states and the District of Columbia have legalized medical cannabis programs, with varying qualifying condition lists, possession limits, and regulatory structures. New York's Compassionate Care Act, enacted in 2014 and significantly expanded through subsequent amendments and the 2021 Marijuana Regulation and Taxation Act, established one of the nation's more restrictive medical cannabis programs. The program initially limited qualifying conditions to a short list of serious conditions including cancer, HIV/AIDS, ALS, Parkinson's disease, multiple sclerosis, spinal cord injury, epilepsy, inflammatory bowel disease, neuropathy, and Huntington's disease. The 2021 law expanded qualifying conditions and authorized the Office of Cannabis Management to sponsor clinical research using state-licensed cannabis products. The FDA regulates cannabis products that make medical claims under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq. Cannabis products marketed with disease treatment claims are considered unapproved new drugs subject to FDA enforcement action. The FDA has approved three cannabis-derived or cannabis-related drug products: Epidiolex (cannabidiol) for seizure disorders, and synthetic THC products Marinol and Syndros for chemotherapy-induced nausea and AIDS-related anorexia. No cannabis product has received FDA approval for IBD treatment. Clinical trials examining cannabis for IBD must comply with FDA Investigational New Drug (IND) regulations under 21 C.F.R. § 312. Researchers must submit an IND application describing the investigational product, preclinical data, manufacturing information, clinical protocol, and investigator qualifications. The FDA reviews the application for safety concerns before allowing the trial to proceed. State-sponsored research initiatives like New York's OCM study operate under these same federal requirements, creating a unique intersection of state policy and federal regulatory oversight. Research participants in cannabis clinical trials receive legal protection under the IND framework, exempting them from federal prosecution for possessing and using cannabis as part of the approved research protocol. However, this protection does not extend to state-level prosecution, making state medical marijuana laws important complementary protections for research participants.

State-by-State Medical Cannabis Access for IBD

Fifteen states explicitly list inflammatory bowel disease, Crohn's disease, or ulcerative colitis as qualifying conditions for medical cannabis access, while additional states allow physician discretion for debilitating conditions.

New York

New York included inflammatory bowel disease among qualifying conditions when its medical marijuana program launched in 2016. Patients must register with the state's medical cannabis program and obtain a certification from a registered practitioner. The state does not impose possession limits for certified patients. New York transitioned to adult-use legalization in 2021 but maintained its separate medical program with tax exemptions for medical patients. The Office of Cannabis Management's 2026 clinical study represents the state's most significant investment in cannabis-IBD research, with recruitment targeting 300 patients across multiple medical centers.

Pennsylvania

Pennsylvania added Crohn's disease and ulcerative colitis as qualifying conditions in 2018 following patient advocacy campaigns. The state's Medical Marijuana Act, 35 P.S. § 10231.303, allows certified patients to purchase up to a 90-day supply of medical cannabis products. Pennsylvania prohibits smoking of medical cannabis, limiting patients to vaporization, tinctures, capsules, topicals, and other non-combustible forms. Approximately 8,400 Pennsylvania medical cannabis patients listed IBD as their qualifying condition as of March 2026, according to state Department of Health data.

Ohio

Ohio included inflammatory bowel disease in its medical marijuana program when it became operational in 2019 under Ohio Rev. Code § 3796. Patients may possess up to a 90-day supply as determined by their recommending physician. Ohio requires that all medical cannabis products undergo testing for potency, contaminants, and pesticides. The state's Board of Pharmacy, which regulates the medical marijuana program, has approved research protocols examining cannabis use patterns among IBD patients, though no state-sponsored clinical trials have been initiated.

Illinois

Illinois added Crohn's disease to its medical cannabis qualifying conditions in 2015. The state's Compassionate Use of Medical Cannabis Program Act, 410 ILCS 130, allows certified patients to possess up to 2.5 ounces of cannabis flower every 14 days. Illinois transitioned to adult-use legalization in 2020 but maintained medical program benefits including higher possession limits and lower taxes. The University of Illinois at Chicago has conducted observational studies of medical cannabis use among IBD patients enrolled in the state program.

Massachusetts

Massachusetts includes inflammatory bowel disease among debilitating conditions qualifying for medical marijuana under 105 CMR 725.000. The state does not impose specific possession limits for medical patients, instead allowing physicians to determine appropriate quantities. Massachusetts legalized adult-use cannabis in 2016, creating a dual medical and recreational market. The state's Cannabis Control Commission has funded research examining medical cannabis use patterns but has not sponsored IBD-specific clinical trials.

California

California's Compassionate Use Act of 1996 and subsequent Medical Marijuana Program Act do not list specific qualifying conditions. Instead, physicians may recommend cannabis for any condition for which marijuana provides relief, including IBD. This broad discretion made California an early access point for IBD patients seeking cannabis treatment. The University of California San Diego's ongoing clinical trial examining CBD for ulcerative colitis represents the most rigorous California-based IBD research to date. California medical cannabis patients may possess up to eight ounces of dried cannabis and maintain up to six mature plants.

Other States with IBD Access

Additional states providing medical cannabis access for IBD include Connecticut, Delaware, Maine, Michigan, Minnesota, Montana, Nevada, New Hampshire, New Jersey, and Vermont. Each state maintains distinct qualifying condition lists, possession limits, and regulatory requirements. Some states like Minnesota operate state-run dispensary systems, while others like Michigan license private businesses. Possession limits range from one ounce in some states to unlimited quantities with physician authorization in others.

Market and Business Implications

The IBD patient population represents a significant medical cannabis market segment, with an estimated 300,000-450,000 potential medical cannabis patients nationwide based on current state program enrollment patterns. Medical cannabis sales data from state programs show that IBD patients typically spend $200-$400 monthly on cannabis products, favoring tinctures, capsules, and vaporizable concentrates over smokable flower. This preference reflects the patient population's focus on consistent dosing and discreet administration. Tinctures allow precise titration of cannabinoid doses, while capsules provide standardized dosing similar to conventional pharmaceuticals. Multi-state operators including Curaleaf, Trulieve, and Cresco Labs have developed product lines targeting medical conditions including IBD. These products typically feature balanced THC:CBD ratios (commonly 1:1 or 2:1 CBD:THC) based on the hypothesis that CBD's anti-inflammatory properties combined with THC's pain-relieving and anti-nausea effects provide synergistic benefits. Products are marketed with names like "Digest" or "Relief" to signal intended use without making explicit disease claims that would trigger FDA enforcement. The clinical research pipeline has significant implications for cannabis industry valuations. Positive results from rigorous clinical trials could expand the addressable patient population and provide scientific validation that increases mainstream medical acceptance. Conversely, negative trial results could undermine the medical cannabis market segment and reduce patient demand. Industry analysts estimate that definitive clinical evidence supporting cannabis efficacy for IBD could expand the medical cannabis market by $800 million to $1.2 billion annually. Pharmaceutical companies face strategic decisions regarding cannabinoid-based IBD therapies. GW Pharmaceuticals' decision to discontinue its CBD program for ulcerative colitis after disappointing Phase 2 results illustrates the risks of cannabinoid drug development. The company's Epidiolex, approved for epilepsy, demonstrated clear efficacy in reducing seizure frequency—a dramatic, measurable endpoint. IBD presents more complex challenges, with multiple disease phenotypes, variable disease activity, and subjective symptom measures that complicate clinical trial design. Some pharmaceutical companies are exploring synthetic cannabinoids or cannabinoid analogs that may offer advantages over plant-derived products. These molecules can be patented, providing intellectual property protection that natural cannabinoids lack. However, synthetic cannabinoids may not replicate the "entourage effect"—the hypothesis that multiple cannabis compounds work synergistically—that some researchers believe is important for therapeutic efficacy. Insurance coverage remains a critical market barrier. No major health insurer covers medical cannabis products for any condition, including IBD, due to the lack of FDA-approved indications and federal illegality. Patients pay entirely out-of-pocket, creating affordability barriers particularly for lower-income individuals. If cannabis-based therapies receive FDA approval for IBD, insurance coverage would become mandatory under the Affordable Care Act's essential health benefits requirements, dramatically expanding market access. The medical cannabis industry has invested in patient education and physician outreach programs. Companies sponsor continuing medical education programs for gastroenterologists, fund patient advocacy organizations, and develop educational materials explaining endocannabinoid system biology and cannabis product selection. These initiatives aim to increase physician comfort with cannabis discussions and patient knowledge about product options. Vertical integration strategies among cannabis companies affect product consistency and quality control—critical factors for medical applications. Vertically integrated operators control cultivation, processing, and retail, allowing tighter control over cannabinoid profiles and contaminant testing. This integration may provide advantages in serving medical markets where product consistency is paramount.

What Experts Say

Medical experts emphasize that while cannabis shows promise for symptom management in IBD, current evidence does not support it as a disease-modifying therapy or replacement for conventional treatments. Dr. Timna Naftali, a gastroenterologist at Meir Medical Center in Israel who led pioneering clinical trials, has stated in published research that cannabis appears to improve quality of life and reduce symptoms in Crohn's disease patients but does not induce remission or reduce objective inflammatory markers. According to her research published in Clinical Gastroenterology and Hepatology, cannabis may serve as an adjunct therapy for symptom control but should not replace immunosuppressive or biologic therapies that target underlying disease mechanisms. Researchers at the University of Calgary who conducted systematic reviews of cannabis-IBD evidence have noted that the quality of available clinical trials remains limited. According to their 2018 publication in the European Journal of Gastroenterology & Hepatology, most studies have been small, short-duration, and relied on subjective outcome measures. The researchers emphasized the need for larger trials with objective endpoints including endoscopic assessment and histological examination of intestinal tissue. The American Gastroenterological Association's 2020 clinical guidance document, developed by a multidisciplinary expert panel, concluded that insufficient evidence exists to recommend cannabis for IBD treatment. The guidance noted that while cannabis may provide symptomatic relief for some patients, it should not be considered a substitute for evidence-based therapies. The AGA panel recommended that gastroenterologists discuss cannabis use with patients, document usage patterns, and monitor for potential adverse effects including cognitive impairment and cannabis use disorder. Dr. Jami Kinnucan, a gastroenterologist at the University of Michigan who studies cannabis use among IBD patients, has published research showing that approximately 15% of IBD patients report current cannabis use. According to her research in Inflammatory Bowel Diseases journal, patients most commonly use cannabis for pain management, anxiety reduction, and appetite stimulation. However, she noted that many patients reduce or discontinue conventional IBD medications when using cannabis, potentially placing themselves at risk for disease progression and complications. Pharmacology researchers studying cannabinoid mechanisms in intestinal inflammation have identified multiple pathways through which cannabinoids might exert therapeutic effects. According to research published in Nature Reviews Gastroenterology & Hepatology, cannabinoids modulate intestinal motility through CB1 receptors, reduce immune cell activation through CB2 receptors, and may strengthen intestinal barrier function. However, researchers note that translating these mechanisms into effective therapies requires understanding optimal cannabinoid ratios, dosing regimens, and delivery methods. Patient advocacy leaders have emphasized the importance of patient autonomy and access to potential therapies. According to statements from the Crohn's and Colitis Foundation, while the organization supports rigorous research, it also recognizes that patients with severe, refractory disease may choose to explore cannabis treatment in consultation with their physicians. The foundation has advocated for reduced regulatory barriers to cannabis research and increased federal funding for clinical trials. Regulatory experts have noted that state-sponsored research initiatives like New York's OCM study represent novel approaches to generating clinical evidence. According to analysis published in the Journal of Law, Medicine & Ethics, state-funded cannabis research operates in a unique legal space, subject to both state policy objectives and federal regulatory requirements. These initiatives may accelerate evidence generation but also raise questions about research independence and potential conflicts of interest when state agencies that license cannabis businesses also sponsor research on cannabis efficacy.

What's Next

The next 18-24 months will see results from multiple ongoing clinical trials, potential FDA guidance on cannabis research protocols, and continued state-level policy expansion for medical cannabis access. New York's Office of Cannabis Management expects to complete enrollment for its IBD clinical study by December 2026, with preliminary results anticipated in late 2027. The study will examine three different cannabinoid formulations: THC-dominant (20% THC, 1% CBD), CBD-dominant (20% CBD, 1% THC), and balanced ratio (10% THC, 10% CBD). Researchers will assess both subjective measures including symptom scores and quality of life, and objective measures including fecal calprotectin levels and endoscopic disease activity. The trial's design includes a six-month treatment phase followed by a six-month observational period to assess durability of any observed effects. The University of California San Diego trial comparing CBD isolate to full-spectrum cannabis extract for ulcerative colitis is expected to report results in mid-2027. This study will help address the "entourage effect" hypothesis by directly comparing isolated CBD to whole-plant extracts containing multiple cannabinoids and terpenes. The results may inform product development strategies and guide clinical recommendations about optimal cannabinoid formulations. Federal policy developments will significantly impact the research landscape. The DEA's ongoing review of cannabis scheduling, initiated following the Department of Health and Human Services' August 2023 recommendation to reschedule cannabis to Schedule III, could reduce regulatory barriers to clinical research. Rescheduling to Schedule III under 21 U.S.C. § 812(b)(3) would acknowledge accepted medical use and lower abuse potential, potentially streamlining DEA licensing for researchers and expanding the number of approved cannabis suppliers for research purposes. The FDA is expected to issue guidance on cannabis clinical trial design in 2026, addressing methodological challenges including appropriate control groups, outcome measures, and dosing strategies. Such guidance would standardize research approaches and potentially accelerate the drug development pathway for cannabinoid-based therapies. Additional states are considering legislation to add IBD to medical cannabis qualifying condition lists. Advocacy organizations have active campaigns in Florida, Texas, and North Carolina—states with limited medical cannabis programs that are considering expansion. Patient testimony and emerging clinical evidence are central to these legislative efforts. Pharmaceutical companies are monitoring clinical trial results to inform investment decisions. Positive results from academic trials could trigger renewed pharmaceutical industry interest in cannabinoid-based IBD therapies, potentially leading to larger Phase 3 trials necessary for FDA approval. Conversely, negative results could redirect research focus toward other conditions or alternative cannabinoid formulations. The Crohn's and Colitis Foundation plans to convene a scientific workshop in fall 2026 bringing together gastroenterologists, cannabis researchers, and patient advocates to review current evidence and identify research priorities. The foundation has allocated $3.5 million for cannabis-related research grants in its 2026-2027 funding cycle, representing a significant increase from previous years. Long-term observational studies tracking medical cannabis users with IBD will provide real-world evidence about safety and effectiveness outside controlled trial settings. Several academic medical centers have established patient registries collecting longitudinal data on cannabis use patterns, symptom trajectories, and medication changes among IBD patients. These registries will generate valuable data about cannabis use in clinical practice, complementing randomized controlled trial evidence. The intersection of cannabis research and precision medicine approaches may yield insights about which IBD patients are most likely to benefit from cannabinoid therapies. Researchers are investigating whether genetic variations in endocannabinoid system genes, disease phenotypes (Crohn's disease versus ulcerative colitis, inflammatory versus stricturing disease), or other biomarkers predict treatment response. Such research could enable personalized treatment recommendations rather than one-size-fits-all approaches.

Further Reading

• New York Office of Cannabis Management: https://cannabis.ny.gov — Official state regulator website with medical cannabis program information and research initiatives
• Crohn's and Colitis Foundation: https://www.crohnscolitisfoundation.org — Patient advocacy organization with disease information and research updates
• National Institute on Drug Abuse: https://nida.nih.gov/research-topics/marijuana — Federal research agency with cannabis science resources
• American Gastroenterological Association: https://gastro.org — Professional organization with clinical guidance on cannabis and IBD
• ClinicalTrials.gov: https://clinicaltrials.gov — Federal registry of ongoing clinical trials; search "cannabis inflammatory bowel disease" for current studies
• Naftali T, et al. "Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study." Clinical Gastroenterology and Hepatology. 2013;11(10):1276-1280 — Landmark Israeli clinical trial
• Kafil TS, et al. "Cannabis for the treatment of Crohn's disease." Cochrane Database of Systematic Reviews. 2018;11:CD012853 — Comprehensive evidence review
• Storr M, et al. "Cannabis use provides sympt